The Global Low Molecular Weight Heparin Market, by Drug (Enoxaparin, Dalteparin, Nadroparin, Bemiparin, Tinzaparin
, and Others), by Packaging (Multi-vials and Prefilled Syringes), by Application (Deep Vein Thrombosis, Acute Coronary Syndrome (ACS), Pulmonary Embolism and Atrial Fibrillation), by End Use (Hospitals (Private and Public), Clinics, and Home) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued US$ 3,050.4 million in 2018, and is projected to exhibit a CAGR of 6.7% during the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
He had been given the drug Tinzaparin
by medical staff in an effort to break down a clot - known as a pulmonary embolism.
reported that a therapeutic dosage of LMWH (tinzaparin
) reversed cisplatin resistance in a clone of ovarian cancer cell line to the level of sensitive cells [51, 52].
ASA was stopped and he received treatment with low molecular weight heparin (LMWH) (tinzaparin
She was treated with Tinzaparin
12000 units (treatment dose) and was discharged home after a week with warfarin (target INR of 2.0-3.0) for a target period of 6 months and hormone replacement therapy discontinued.
The patientwas started on LMWH (Tinzaparin
18000 units) during his hospitalization.
Daily 75 mg of rectal indomethacin, 1500 cc/day intravenous saline infusion adjusted by considering the electrolyte balance, follow-up of fluid input and output, daily measurement of weight and waist circumference, and 3500 IU/day of low molecular weight heparin (tinzaparin
sodium) for thromboembolism prophylaxis were administered.
in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Specifically, subcutaneous LMWH (enoxaparin [Lovenox[R]], dalteparin [Fragmin[R]], and tinzaparin
[Innohep[R]]) is considered better than intravenous, continuous UFH; the latter is preferred only in patients with complicating factors such as renal insufficiency.
It has been studied in combination with aspirin, low molecular weight heparin (tinzaparin
), and intravenous (i.v.) r-tPA therapy in several dosing regimens, since r-tPA alone is inadequate to recanalize large arterial occlusions in approximately 50% of cases.
Moreover, a study using PCL, PVA, and Eudragit nanoparticles with tinzaparin
(200 to 600 IU/Kg) with a diameter of approximately 400 nm showed oral absorption and anticoagulant activity in rabbits, demonstrated by an increase in anti-Xa activity in plasma .